Combining miR-10b-targeted nanotherapy with low-dose doxorubicin elicits durable regressions of metastatic breast cancer

Cancer Research

Volumn 75, Issue 20, 2015, Pages 4407-4415

  Yoo, Byunghee ^a   Kavishwar, Amol ^a   Ross, Alana ^a   Wang, Ping ^a   Tabassum, Doris P ^a   Polyak, Kornelia ^a   Barteneva, Natalia ^b   Petkova, Victoria ^a   Pantazopoulos, Pamela ^a   Tena, Aseda ^c   Moore, Anna ^a   Medarova, Zdravka ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BOSTON CHILDREN S HOSPITAL   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; MICRORNA 10B; ANTINEOPLASTIC ANTIBIOTIC; MICRORNA; MIRN10 MICRORNA, HUMAN; NANOPARTICLE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER REGRESSION; CELL CYCLE ARREST; CELL VIABILITY; CONTROLLED STUDY; DISTANT METASTASIS; DRUG EFFICACY; DRUG MECHANISM; DRUG TARGETING; FEMALE; GENE FUNCTION; GENE OVEREXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; LOW DRUG DOSE; LYMPH NODE METASTASIS; METASTASIS POTENTIAL; MOUSE; MURINE MODEL; NANOMEDICINE; NONHUMAN; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TREATMENT DURATION; ANIMAL; BREAST NEOPLASMS; CELL CYCLE; CELL MOTION; CELL PROLIFERATION; DISEASE MODEL; DRUG EFFECTS; DRUG SCREENING; GENE INACTIVATION; GENETICS; METASTASIS; PATHOLOGY; PHENOTYPE; TUMOR CELL LINE; TUMOR VOLUME;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; APOPTOSIS; BREAST NEOPLASMS; CELL CYCLE; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; DOXORUBICIN; FEMALE; GENE KNOCKOUT TECHNIQUES; HUMANS; MICE; MICRORNAS; NANOPARTICLES; NEOPLASM METASTASIS; PHENOTYPE; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84945559162     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-15-0888     Document Type: Article

References (22)

1. Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer 2006;6:857-66.
2. Esquela-Kerscher A, Slack FJ. Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer 2006;6:259-69.
3. Medina PP, Nolde M, Slack FJ. OncomiR addiction in an in vivo model of microRNA-21-induced pre-B-cell lymphoma. Nature 2010;467:86-90.
4. Ma L, Teruya-Feldstein J, Weinberg RA. Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature 2007;449:682-8.
5. Ma L, Reinhardt F, Pan E, Soutschek Jr, Bhat B, Marcusson EG, et al. Therapeutic silencing of miR-10b inhibits metastasis in a mousemammary tumor model. Nat Biotechnol 2010;28:341-7.
6. Yigit MV, Ghosh SK, Kumar M, Petkova V, Kavishwar A, Moore A, et al. Context-dependent differences in miR-10b breast oncogenesis can be targeted for the prevention and arrest of lymph node metastasis. Oncogene 2013;32:1530-8.
7. Yoo B, Ghosh SK, Kumar M, Moore A, Yigit MV, Medarova Z. Design of nanodrugs for miRNA targeting in tumor cells. J Biomed Nanotechnol 2014;10:1114-22.
8. Ghosh SK, Yigit MV, Uchida M, Ross AW, Barteneva N, Moore A, et al. Sequence-dependent combination therapy with doxorubicin and a survivin-specific small interfering RNA nanodrug demonstrates efficacy in models of adenocarcinoma. Int J Cancer 2014;134:1758-66.
9. Yoo B, Kavishwar A, Ross A, Pantazopoulos P, Moore A, Medarova Z. In vivo detection of miRNA expression in tumors using an activatable nanosensor. Mol Imaging Biol. 2015 May 19. [Epub ahead of print].
10. Yoo B, Ifediba MA, Ghosh S, Medarova Z, Moore A. Combination treatment with theranostic nanoparticles for glioblastoma sensitization to TMZ. Mol Imaging Biol 2014;16:680-9.
11. Medarova Z, Pham W, Farrar C, Petkova V, Moore A. In vivo imaging of siRNA delivery and silencing in tumors. Nat Med 2007;13:372-7.
12. Kumar M, Yigit M, Dai G, Moore A, Medarova Z. Image-guided breast tumor therapy using a small interfering RNA nanodrug. Cancer Res 2010; 70:7553-61.
13. Branca RT, Cleveland ZI, Fubara B, Kumar CS, Maronpot RR, Leuschner C, et al. Molecular MRI for sensitive and specific detection of lung metastases. Proc Natl Acad Sci U S A 2010;107:3693-7.
14. Leuschner C, Kumar CS, Hansel W, Soboyejo W, Zhou J, Hormes J. LHRH-conjugated magnetic iron oxide nanoparticles for detection of breast cancer metastases. Breast Cancer Res Treat 2006;99: 163-76.
15. Arbab AS, Bashaw LA, Miller BR, Jordan EK, Lewis BK, Kalish H, et al. Characterization of biophysical and metabolic properties of cells labeled with superparamagnetic iron oxide nanoparticles and transfection agent for cellular MR imaging. Radiology 2003;229: 838-46.
16. Gabriely G, Yi M, Narayan RS, Niers JM, Wurdinger T, Imitola J, et al. Human glioma growth is controlled by microRNA-10b. Cancer Res 2011;71:3563-72.
17. Baffa R, Fassan M, Volinia S, O'Hara B, Liu CG, Palazzo JP, et al. MicroRNA expression profiling of human metastatic cancers identifies cancer gene targets. J Pathol 2009;219:214-21.
18. Krepler C, Wacheck V, Strommer S, Hartmann G, Polterauer P, Wolff K, et al. CpG oligonucleotides elicit antitumor responses in a human melanoma NOD/SCID xenotransplantation model. J Invest Dermatol 2004; 122:387-91.
19. Ma L, Weinberg RA. MicroRNAs in malignant progression. Cell Cycle 2008;7:570.
20. Moriarty CH, Pursell B, Mercurio AM. miR-10b targets tiam1 implications for Rac activation and carcinoma migration. J Biol Chem 2010; 285:20541-6.
21. Tian Y, Luo A, Cai Y, Su Q, Ding F, Chen H, et al. MicroRNA-10b promotes migration and invasion through KLF4 in human esophageal cancer cell lines. J Biol Chem 2010;285:7986-94.
22. Guessous F, Alvarado-Velez M, Marcinkiewicz L, Zhang Y, Kim J, Heister S, et al. Oncogenic effects of miR-10b in glioblastoma stem cells. J Neurooncol 2013;112:153-63.